The Apelin-APJ System in the Evolution of Heart Failure

Overview

Journal Clujul Med

Specialty General Medicine

Date 2015 Nov 4

PMID 26528040

Citations 18

Authors

Cerasela Mihaela Goidescu

Luminita Animarie Vida-Simiti

Affiliations

Soon will be listed here.

Abstract

Heart failure is a chronic, progressive disease in which the overexpression of biologically active molecules and neurohomonal activation are the key factors of the evolution and natural history. The apelin-APJ system is a newly discovered molecular pathway and the RAAS counterbalance is its principal effect. The apelin is a potent inotrope, vasodilator and diuretic with crucial cardioprotective effects against angiotensin and aldosterone injuries. Intense and prolonged RAAS induces the downregulation of the apelin and its receptor at myocardial level and cancels their protection. Compared to the vasoactive agents used in the treatment of acute heart failure, exogen apelin has unique intropic and vasodilatory effects without deleterious consequences, being a promising therapeutic option.

Citing Articles

Novel insights into the central protective role of ACE2 in diabetic cardiomyopathy: from underlying signaling pathways to therapeutic perspectives.

Li X, Qu S Mol Cell Biochem. 2025; .

PMID: 39928210 DOI: 10.1007/s11010-024-05196-6.

Adipokines and Their Role in Heart Failure: A Literature Review.

Rafaqat S J Innov Card Rhythm Manag. 2023; 14(11):5657-5669.

PMID: 38058391 PMC: 10697129. DOI: 10.19102/icrm.2023.14111.

Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure.

Berezina T, Fushtey I, Berezin A, Pavlov S, Berezin A Adv Ther. 2023; 41(1):292-314.

PMID: 37935870 PMC: 10796534. DOI: 10.1007/s12325-023-02683-y.

Structure-function relationship and physiological role of apelin and its G protein coupled receptor.

Murali S, Aradhyam G Biophys Rev. 2023; 15(1):127-143.

PMID: 36919024 PMC: 9995629. DOI: 10.1007/s12551-023-01044-x.

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure.

Berezin A, Fushtey I, Berezin A Biomedicines. 2022; 10(7).

PMID: 35885056 PMC: 9313111. DOI: 10.3390/biomedicines10071751.

References

Dai T, Ramirez-Correa G, Gao W . Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006; 553(1-3):222-8. PMC: 1815301. DOI: 10.1016/j.ejphar.2006.09.034. View

ODowd B, Heiber M, Chan A, Heng H, Tsui L, Kennedy J . A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993; 136(1-2):355-60. DOI: 10.1016/0378-1119(93)90495-o. View

Yu X, Tang Z, Liu L, Qian H, Tang S, Zhang D . Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta. 2013; 428:1-8. DOI: 10.1016/j.cca.2013.09.001. View

Desai A, Stevenson L . Rehospitalization for heart failure: predict or prevent?. Circulation. 2012; 126(4):501-6. DOI: 10.1161/CIRCULATIONAHA.112.125435. View

Stewart S, Macintyre K, Hole D, Capewell S, McMurray J . More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001; 3(3):315-22. DOI: 10.1016/s1388-9842(00)00141-0. View

Masri B, Knibiehler B, Audigier Y . Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal. 2004; 17(4):415-26. DOI: 10.1016/j.cellsig.2004.09.018. View

Siddiquee K, Hampton J, McAnally D, May L, Smith L . The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol. 2012; 168(5):1104-17. PMC: 3594671. DOI: 10.1111/j.1476-5381.2012.02192.x. View

Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou M . Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251(2):471-6. DOI: 10.1006/bbrc.1998.9489. View

Perjes A, Skoumal R, Tenhunen O, Konyi A, Simon M, Horvath I . Apelin increases cardiac contractility via protein kinase Cε- and extracellular signal-regulated kinase-dependent mechanisms. PLoS One. 2014; 9(4):e93473. PMC: 3973555. DOI: 10.1371/journal.pone.0093473. View

10.

Aalbers J . New ESC heart failure guidelines with South African expert comment. Cardiovasc J Afr. 2012; 23(5):295-6. View

11.

Masri B, Morin N, Pedebernade L, Knibiehler B, Audigier Y . The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem. 2006; 281(27):18317-26. DOI: 10.1074/jbc.M600606200. View

12.

Lloyd-Jones D, Adams R, Carnethon M, de Simone G, Ferguson T, Flegal K . Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 119(3):e21-181. DOI: 10.1161/CIRCULATIONAHA.108.191261. View

13.

Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H . Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002; 91(5):434-40. DOI: 10.1161/01.res.0000033522.37861.69. View

14.

Pisarenko O, Serebryakova L, Studneva I, Pelogeykina Y, Tskitishvili O, Bespalova Z . Effects of structural analogues of apelin-12 in acute myocardial infarction in rats. J Pharmacol Pharmacother. 2013; 4(3):198-203. PMC: 3746303. DOI: 10.4103/0976-500X.114600. View

15.

Bodineau L, Hus-Citharel A, Llorens-Cortes C . [Contribution of apelin to water balance, blood glucose control, and cardiovascular functions]. Ann Endocrinol (Paris). 2010; 71(4):249-56. DOI: 10.1016/j.ando.2010.03.004. View

16.

Wang W, McKinnie S, Patel V, Haddad G, Wang Z, Zhabyeyev P . Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc. 2013; 2(4):e000249. PMC: 3828798. DOI: 10.1161/JAHA.113.000249. View

17.

Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt K . Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun. 2003; 308(3):480-5. DOI: 10.1016/s0006-291x(03)01424-4. View

18.

Poulain D, Wakerley J, Dyball R . Electrophysiological differentiation of oxytocin- and vasopressin-secreting neurones. Proc R Soc Lond B Biol Sci. 1977; 196(1125):367-84. DOI: 10.1098/rspb.1977.0046. View

19.

Alfarano C, Foussal C, Lairez O, Calise D, Attane C, Anesia R . Transition from metabolic adaptation to maladaptation of the heart in obesity: role of apelin. Int J Obes (Lond). 2014; 39(2):312-20. PMC: 4326962. DOI: 10.1038/ijo.2014.122. View

20.

De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C . Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A. 2004; 101(28):10464-9. PMC: 478592. DOI: 10.1073/pnas.0403518101. View